

**RISK EVALUATION AND MITIGATION STRATEGY (REMS)  
for XIAFLEX™ (collagenase clostridium histolyticum), under BLA 125338**

Auxilium Pharmaceuticals, Inc.  
40 Valley Stream Parkway  
Malvern, PA 19355

**Contact Information:**

Benjamin J. Del Tito, Jr., Ph.D.  
Senior Vice President Quality and Regulatory Affairs  
Auxilium Pharmaceuticals, Inc.  
(484-321-5900)

## **I. GOALS**

To inform healthcare providers about the risks of tendon rupture, serious adverse reactions affecting the injected extremity, and the potential risk of serious hypersensitivity reactions (including the potential for anaphylaxis) associated with XIAFLEX.

To inform healthcare providers about how to properly inject XIAFLEX and perform finger extension procedures.

To inform patients about the serious risks associated with XIAFLEX.

## **II. REMS ELEMENTS**

### **A. MEDICATION GUIDE**

In accordance with 21 CFR 208.24, a Medication Guide will be attached to the Package Insert and will be provided by Auxilium Pharmaceuticals, Inc.

- The Medication Guide will be included in each single unit carton containing XIAFLEX and dispensed in accordance with 21 CFR 208.24.
- The carton will include a prominent notice to authorized dispensers to “Dispense the enclosed Medication Guide to each patient.”
- The Medication Guide will also be available through the product website ([www.XIAFLEX.com](http://www.XIAFLEX.com)), the Sponsor’s toll-free medical information line (1-877-XIAFLEX; 1-877-942-3539), and Sales and/or Medical Affairs representatives.

Please refer to the appended Medication Guide ([Appendix A](#)).

### **B. COMMUNICATION PLAN**

In accordance with FDCA 505-1(e)(3), Auxilium will implement a Communication Plan to convey important information about the risks associated with XIAFLEX [tendon rupture, serious adverse reactions affecting the injected extremity, and the potential risk of serious hypersensitivity reactions (including the potential for anaphylaxis)] and to disseminate education materials about how to properly inject XIAFLEX and perform finger extension procedures.

The initial target audience for this Communication Plan will include healthcare providers who are likely to prescribe XIAFLEX including hand surgeons, orthopedic surgeons, plastic surgeons, general surgeons, and rheumatologists.

Elements of the communication plan:

1. A Dear Healthcare Provider Letter ([Attachment 1](#)) will be distributed via hardcopy mailings at the time of first marketing, within 60 days of the REMS approval. Full Prescribing Information and a copy of the Medication Guide will also be distributed in this communication. This letter will also include information about how to obtain the

educational materials (see below). In addition, any known new provider inquiring about the use of XIAFLEX will also receive the Dear Healthcare Provider Letter and have access to the educational materials, including the Training Guide and Training Video.

2. Educational Materials include:

- Training Guide for the Administration of XIAFLEX ([Attachment 2](#))
- XIAFLEX Procedure Training Video (see [Attachment 3](#) for Training Video screenshots and transcript)

The Training Guide and Training Video are “stand-alone” tools and although both may be used by a provider, each provides complete training instructions and information regarding the risks addressed in the REMS. These materials will be available within 60 days of REMS approval through the following distribution methods:

- A separate REMS link accessed through the [www.XIAFLEX.com](http://www.XIAFLEX.com) website ([Attachment 4](#))
- Sales and Medical Affairs representatives
- Hard copy mailing, upon request, through Auxilium’s toll-free medical information line (1-877-XIAFLEX; 1-877-942-3539)

**C. ELEMENTS TO ASSURE SAFE USE**

Elements to Assure Safe Use are not required.

**D. IMPLEMENTATION SYSTEM**

An Implementation System is not required.

**E. TIMETABLE FOR SUBMISSION OF ASSESSMENTS**

Auxilium will submit REMS Assessments to FDA annually for years 1 through 5 and at 7 years from the date of the approval of the REMS. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. Auxilium will submit each assessment so that it will be received by the FDA on or before the due date.